Drug intelligence / Profile preview

Oncosyn

Development stage: Unknown
Lead developer: Altimmune
Modality: Peptides

Overview

**Oncosyn** is a preclinical immuno-oncology program developed using Altimmune's proprietary Densigen synthetic peptide technology platform. It is designed to leverage peptide-based immunotherapeutics to stimulate immune responses against cancer cells, targeting immuno-oncology indications in solid tumors. The program was part of Altimmune's pipeline following the 2017 merger with PharmAthene, with a focus on next-generation cancer immunotherapies, though specific clinical advancement details beyond preclinical stage are limited.

Beyond the preview

Go deeper on Oncosyn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncosyn.

Explore the full profile